The global personalized medicine market size was estimated at USD 567.10 billion in 2024 and is projected to reach USD 1,196.18 billion by 2033, growing at a CAGR of 8.80% from 2025 to 2033. The market’s rapid growth is primarily driven by the increasing demand for targeted therapies and precision diagnostics, which allow for more individualized and effective treatment approaches.

Advancements in genomic technologies, biomarker identification, and data-driven treatment strategies have revolutionized healthcare by enabling clinicians to design therapies specifically tailored to individual patient profiles. This approach not only enhances treatment efficacy and minimizes side effects but also ensures a more efficient allocation of healthcare resources. As the global incidence of chronic and complex diseases continues to rise, the adoption of personalized medical solutions is gaining momentum, spurring innovation and investment across multiple segments such as diagnostics, therapeutics, and integrated health data platforms.

The growing prevalence of chronic conditions such as cancer, diabetes, and cardiovascular diseases is further driving the need for individualized treatment strategies. Personalized diagnostics play a key role in improving disease detection accuracy, enabling earlier interventions and better patient outcomes. For instance, in 2024, Illumina’s FDA-approved TruSight Oncology Comprehensive test demonstrated this capability by analyzing over 500 genes to guide targeted cancer treatments, exemplifying the precision offered by modern diagnostic tools.

Additionally, rising patient awareness of genetic predispositions and the growing accessibility of DNA-based testing services are supporting the wider adoption of personalized healthcare. This shift toward proactive, patient-centered care is reshaping modern medicine by promoting early disease detection, prevention, and customized treatment pathways. Consequently, the personalized medicine market is poised for continued expansion across diverse medical disciplines, reflecting a broader transformation toward more precise, data-informed, and patient-specific healthcare delivery.

Key Market Trends & Insights:

• In 2024, North America dominated the global personalized medicine market, accounting for the largest share of 40.17%. The region’s leadership position can be attributed to the strong presence of advanced healthcare infrastructure, high adoption of precision diagnostic technologies, and continuous investments in genomics and biotechnology research. Moreover, supportive government initiatives, favorable reimbursement policies, and the growing focus on patient-centered care have further strengthened North America’s dominance in the market.

• Within the region, the U.S. personalized medicine industry is anticipated to experience significant growth over the forecast period. This expansion is driven by the increasing integration of genomic testing, artificial intelligence, and data analytics into clinical practices. The country also benefits from a robust research ecosystem, the presence of major biopharmaceutical companies, and strong collaborations between research institutions and healthcare providers aimed at advancing personalized treatment solutions.

• By product, the personalized nutrition and wellness segment held the largest market share of 32.0% in 2024. This segment’s growth is primarily driven by the rising consumer awareness regarding preventive healthcare and the growing demand for customized dietary plans and supplements based on individual genetic profiles. The trend toward health optimization and lifestyle management has encouraged the development of personalized nutrition products and digital wellness platforms, contributing to the segment’s market dominance.

• By end use, the hospitals segment accounted for the highest market share in 2024. Hospitals play a pivotal role in implementing personalized medicine approaches due to their access to advanced diagnostic technologies, skilled medical professionals, and integrated patient data systems. The increasing adoption of genetic testing, molecular diagnostics, and targeted therapies in hospital settings has enhanced the precision and effectiveness of treatment outcomes, further reinforcing the segment’s leadership in the personalized medicine market.

Order a free sample PDF of the Personalized Medicine Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 567.10 Billion

• 2033 Projected Market Size: USD 1,196.18 Billion

• CAGR (2025-2033): 8.80%

• North America: Largest market in 2024

• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

Illumina, Inc. and QIAGEN are among the leading players in the personalized medicine market, recognized for their cutting-edge sequencing technologies and molecular diagnostic solutions designed to support individualized treatment pathways. Their innovations enable precise genetic profiling and targeted therapy selection, thereby advancing the effectiveness of personalized healthcare.

GE Healthcare and IBM also hold strong positions in the market through their integrated health data platforms and AI-driven clinical decision support systems. These solutions facilitate the efficient analysis of complex medical data, helping clinicians make informed, evidence-based treatment decisions tailored to each patient’s unique health profile.

Exact Sciences Corporation and Danaher Corporation (through its subsidiary Cepheid, Inc.) continue to strengthen their market presence by offering high-precision diagnostic solutions, particularly in oncology and infectious disease management. Their technologies enable early and accurate detection of diseases, which is critical for guiding targeted and timely interventions.

Abbott and Dako A/S leverage their extensive diagnostic product portfolios and advanced laboratory automation systems to improve the efficiency and accuracy of personalized diagnostics. These innovations help streamline testing workflows, reduce turnaround times, and enhance diagnostic precision, ultimately contributing to improved patient outcomes.

Biogen and Genentech, Inc. are at the forefront of developing targeted therapeutics, focusing on neurodegenerative and oncological diseases. Their continued investments in research and development are driving breakthroughs in precision medicine by aligning treatment strategies with specific genetic and molecular profiles of diseases.

Overall, the personalized medicine market remains highly competitive, fueled by the growing demand for customized care, the increasing adoption of predictive and preventive healthcare approaches, and continuous innovation across diagnostics, therapeutics, and digital health platforms. Strategic collaborations, technological advancements, and data-driven healthcare models are expected to further accelerate market growth in the coming years.

Key Players

• GE Healthcare

• Illumina, Inc.

• ASURAGEN, INC.

• Abbott

• Dako A/S

• Exact Sciences Corporation

• Danaher Corporation (Cepheid, Inc.)

• Decode Genetics, Inc.

• QIAGEN

• Exagen Inc.

• Precision Biologics

• Celera Diagnostics LLC.

• Biogen

• Genelex

• International Business Machines Corporation (IBM)

• Genentech, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The personalized medicine market is poised for sustained growth, driven by increasing demand for targeted therapies and precision diagnostics. Advances in genomics, biomarkers, and data-driven treatment strategies are enabling more individualized healthcare. This shift supports improved treatment outcomes, reduced side-effects, and more efficient resource use in addressing chronic and complex diseases.